Future of R/R DLBCL
A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
Potential Role of CAR T-cell Therapy in the Front-line Setting for Patients with R/R DLBCL
Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.
Sequencing Therapies in Patients with R/R DLBCL
Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.
ZUMA-7: Clinical Implications
Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.
Eligibility Criteria for CAR T-Cell Therapy in R/R DLBCL
An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.
Role of CAR T-cell Therapy in Patients with R/R DLBCL
Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.
L-MIND: Review of Long-Term Analyses Data
Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.
Treatment Options for Patients with R/R DLBCL
Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.
An Overview of R/R DLBCL
Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).
Front-Line Treatment Options for Patients with DLBCL
Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).
Niraparib as Second-line Maintenance Demonstrates Real-world OS Benefit in Recurrent Ovarian Cancer
Eftilagimod Alpha Plus Pembrolizumab Generates Responses, Safety in Metastatic HNSCC
Extended Lymphadenectomy Does Not Lead to Survival Benefit in MIBC
Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma
2 Clarke Drive Cranbury, NJ 08512